Switching biologics in the treatment of psoriatic arthritis

Merola, Joseph F.; Lockshin, Benjamin; Mody, Elinor

doi:10.1016/j.semarthrit.2017.02.001

Cited by 77 publications

(81 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…3). 23 In this study, the reason for switching from other biologics to ADA was inefficacy in all patients. However, some patients with psoriasis show an insufficient response to biologics.…”

Section: Discussionmentioning

confidence: 69%

“…Switching from one TNF-a inhibitor to another TNF-a inhibitor can be effective for a substantial proportion of patients with psoriasis arthritis. 23 In this study, the reason for switching from other biologics to ADA was inefficacy in all patients. In the ADA 40-80 mg group, five patients required switching from other biologics to ADA due to inefficacy in treating skin symptoms (IFX, one psoriasis vulgaris case and two psoriasis arthritis cases; UST, two psoriasis vulgaris cases).…”

Section: Discussionmentioning

confidence: 69%

See 1 more Smart Citation

Results of a retrospective study on the efficacy and safety of adalimumab 80 mg administrated every other week in patients with psoriasis at a single Japanese institution

Karakawa

Komine

Kishimoto

et al. 2019

The Journal of Dermatology

View full text Add to dashboard Cite

Adalimumab (ADA) is one of the tumor necrosis factor (TNF)‐α monoclonal antibodies used for the treatment of psoriasis. In Japan, standard dosing of ADA for adults is an initial s.c. injection of 80 mg, followed by 40 mg every other week. Some patients who initially do not respond to treatment are allowed an increased dose of 80 mg every other week. However, studies on the efficacy and safety of ADA dose escalation to 80 mg every other week are few. In this study, we retrospectively studied 92 patients with psoriasis who received ADA therapy in our hospital. In 45 out of 92 patients, the dose of ADA 80 mg was administrated every other week, and the efficacy was observed within 12 weeks. The most common adverse drug reaction was upper respiratory infection, followed by diarrhea. In three patients, malignancies occurred during the observation period. No deaths or other severe complications were observed. In conclusion, this study showed the efficacy and safety of ADA dose escalation to 80 mg every other week in patients with psoriasis.

show abstract

Section: Discussionmentioning

confidence: 69%

Section: Discussionmentioning

confidence: 69%

Results of a retrospective study on the efficacy and safety of adalimumab 80 mg administrated every other week in patients with psoriasis at a single Japanese institution

Karakawa

Komine

Kishimoto

et al. 2019

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…13 Early recognition of nail disease is important both to prevent long-term physical and psychosocial sequelae, and because growing evidence supports that the presence of nail psoriasis in a patient may be used as a predictor for the development of psoriatic arthritis. 22 Following diagnosis of nail psoriasis, the clinician may create a treatment regimen from the various available topical, intralesional, systemic, and biologic agents. Treatment selection for nail psoriasis is a complex undertaking, but can be conceptualized as a spectrum based on the severity of disease present throughout the body.…”

Section: Patient Education Suggestions For Nail Psoriasismentioning

confidence: 99%

“…This is critical to slowing the progression of the debilitating disease and preventing the irreversible, deforming joint complications associated with it. 22 Diagnosis of nail involvement in a psoriasis patient is made clinically, based on the presence of characteristic physical exam findings. (Note: It is crucial that the patient remove any nail polish prior to examination as the polish can obscure observation of the lesions.)…”

mentioning

confidence: 99%

Clinical Manifestations and Management Considerations of Psoriasis Affecting The Nail Unit

Desai¹,

Rosso²,

Lebwohl³

2019

J of Skin

View full text Add to dashboard Cite

Psoriasis is a chronic, inflammatory disease with a diverse array of clinical manifestations involving the skin, joints, and nails. Of these, nail psoriasis is a frequently overlooked, yet important complication of psoriasis which can cause significant physical and psychological distress to a patient. Psoriasis affecting the nail unit can pose both diagnostic and therapeutic challenges to physicians due to its clinical heterogeneity, the multitude of available treatment options, and the general lack of high-quality research on the subject. In order to aid the practicing clinician in appropriate diagnosis and treatment of nail psoriasis, this review provides an overview of the epidemiological, clinical, and pathophysiologic features of the disease, while also attempting to develop a rationale for effective medical management of the condition.

show abstract

“…The most common reason for switching TNFi is the lack of efficacy, followed by adverse effects. [51][52][53][54] In our previous guideline, we allowed up to a maximum of two TNFi for primary or secondary treatment failures, or three for TNFi intolerance. In the current guideline,…”

Section: Consensus 6 If First-line Treatment With Tnfi Fails Secomentioning

confidence: 99%

Singapore chapter of rheumatologists' updated consensus statement on the eligibility for government subsidization of biologic and targeted therapy for the treatment of psoriatic arthritis

et al. 2019

View full text Add to dashboard Cite

Aim There have been major advances in biologic treatment options for psoriatic arthritis (PsA) since the publication of the 2015 consensus recommendations by the Chapter of Rheumatologists, College of Physicians, Academy of Medicine, Singapore, for government‐assisted funding, thus warranting a revision of this guideline. Methods Recent trials and nine published guidelines on the use of biologic therapy for PsA were reviewed. Based on the synthesized evidence, a task force panel (TFP), consisting of 10 practicing rheumatologists in Singapore, rated the statements pertaining to the use of biologic therapy, using a modified Delphi approach. Consensus was obtained if >70% agreed on a statement. Results The TFP agreed on 10 recommendations pertaining to the initiation, choice and continuation of biologic therapy. A biologic is indicated in patients with PsA: (a) with at least three swollen and tender joints, digits or entheses; and (b) who have failed at least two conventional synthetic disease‐modifying anti‐rheumatic drug (csDMARD) strategies for a minimum of 3 months each. Any approved drug class including tumor necrosis factor inhibitors, interleukin‐17 inhibitors (IL‐17i), IL‐12/23i or targeted synthetic DMARDs may be considered as first‐line treatment, and continued only if a response is achieved by 6 months. Conclusion These recommendations developed through a formal consensus method may be useful to guide funding considerations for appropriate and equitable use of biologic therapy for eligible patients with PsA.

show abstract

Switching biologics in the treatment of psoriatic arthritis

Cited by 77 publications

References 75 publications

Results of a retrospective study on the efficacy and safety of adalimumab 80 mg administrated every other week in patients with psoriasis at a single Japanese institution

Results of a retrospective study on the efficacy and safety of adalimumab 80 mg administrated every other week in patients with psoriasis at a single Japanese institution

Clinical Manifestations and Management Considerations of Psoriasis Affecting The Nail Unit

Singapore chapter of rheumatologists' updated consensus statement on the eligibility for government subsidization of biologic and targeted therapy for the treatment of psoriatic arthritis

Contact Info

Product

Resources

About